Prognostic factors and efficacy of GDP-R therapy in refractory/relapsed diffuse large B-cell lymphomas not eligible for high-dose therapy
暂无分享,去创建一个
P. Ferrari | A. Nicolini | S. Galimberti | M. Petrini | R. Morganti | N. Cecconi | G. Cervetti | F. Ghio | M. Pelosini